# Appendix from Lee et al., "CCN1 suppresses pulmonary vascular smooth muscle contraction in response to hypoxia" <br> (Pulm. Circ., vol. 5, no. 4, p. 000) 

## Supplementary figures



Figure S1. In vivo function of short-term CCN1 treatment in hypoxia-induced pulmonary hypertension in mice. C57BL/6 mice were preexposed with hypoxia ( $10 \%$ ). After 3 weeks, 12 hours before measurement, mice were treated with phosphate-buffered saline or CCN1 recombinant protein ( $1 \mu \mathrm{~g} / \mathrm{kg}$ ) intraperitoneally. Right ventricle weight/body weight (RVW/BW; A), Fulton's index (B), and left ventricular (LV) systolic pressure ( $C$ ) were determined. $n=10$ for each group in $A, B ; n=4$ for each group in $C$. ns: not significant.


Figure S2. Effects of CCN1 in a hypoxia-induced pulmonary hypertension model in rats. Sprague-Dawley rats were exposed to hypoxia ( $10 \%$ ). After 3 weeks, 12 hours before the measurement, CCN1 was administrated intraperitoneally. Right ventricle weight/ body weight (RVW/BW; $A$ ) and Fulton's index $(B)$ were then determined. $n=6$ for each group. ns: not significant.


Figure S3. Effects of CCN1 in hypoxia/su5416-induced pulmonary hypertension in mice. C57BL/ 6 mice were pretreated with su5416 ( $2 \mathrm{mg} / \mathrm{kg}$ ), followed by hypoxia. After 3 weeks, 12 hours before the measurement, CCN1 was administrated intraperitoneally. Right ventricle weight/body weight (RVW/BW; $A$ ) and Fulton's index $(B)$ were then determined. $n=15$ for each group. ns: not significant.



Figure S4. Effects of CCN1 in a monocrotaline (MCT)-induced pulmonary hypertension model in rats. Sprague-Dawley rats were treated with MCT ( $60 \mathrm{mg} / \mathrm{kg}$ subcutaneously). After 3 weeks, 12 hours before the measurement, CCN1 was administrated intraperitoneally. Right ventricle weight/body weight (RVW/BW; $A$ ) and Fulton's index ( $B$ ) were then determined. $n=6$ for each group. ns: not significant.

